Dabur Pharma, a leading player in the domestic oncology segment, is busy finalising its marketing strategies for EU, the US and Australia.
The Telecom Commission is considering imposing fines of Rs 400 crore (Rs 4 billion) on seven telecom service providers for delay in commissioning of services. A note for this purpose was put up for consideration last month.
The government is mulling a policy for developing hydro-power capacity, under which projects, possibly of 2,000-3,000 Mw each, would be drawn up and offered to private and public sector developers.
The Ruias are contemplating approaching the Ministry of Company Affairs for its views on the Right of First Refusal (RoFR) clause in their shareholders' agreement with Hutchison Telecom International Ltd (HTIL).
At present, the service tax rate stands at 12 per cent. Added to this is a 2 per cent education cess, bringing the incidence to 12.24 per cent.
The new pharma policy proposed by Chemicals Minister Ram Vilas Paswan is likely to call for a central mechanism to oversee research and development projects in the country.
It aims at slashing the average market prices from 10 to 30 per cent for low-end brands and from 30 to 60 per cent for high-end ones.
Apart from Roche's hepatitis medicine Pegasys, which received a patent in March 2005, there have been no major announcements on grant of product patents.
Pharma Link, a joint venture of leading pharmaceutical support service provider Interpharma Asia-Pacific
Eli Lily, Sanofi Aventis, Bristol Myers approach chemicals ministry.
Pharma companies' hope to have several of their house hold remedy brands like Crocin made available through grocery shops across the country may not materialise.
All India Organisation of Chemists and Druggists, the apex body of over 500,000 chemists that manage the bulk of the Rs 50,000 crore
Congress president Sonia Gandhi and Prime Minister Manmohan Singh will not be able to attend the annual World Economic Forum meeting to be held at Davos from January 24-28 next year.
The domestic pharmaceuticals industry has proven its mettle once again with Glenmark Pharmaceuticals announcing the receipt of euro 25 million from German drug major Merck
The corporate hospital sector of the country is all set to take away a significant share of the tertiary healthcare service business from individual private healthcare providers by 2010.
This is the same level as the peak rate of the Association of South East Asian Nations.
Pharmaceutical major Wockhardt is looking at foraying into Japan either through exports or by setting up a manufacturing base.
Cheap bulk drug imports from China may soon post a threat to the Rs 20,000 crore (Rs 200 billion) domestic bulk drug industry.
The proposal will help India, one of the most cost-effective location for pharmaceutical production, to increase its growing generic exports multifold in a hassle-free regulatory environment.
Fortis Healthcare Limited is close to picking up a majority stake in Naresh Trehan's upcoming Medicity project in Gurgaon, with the contours of the agreement expected to be finalised within a month.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances